Journal article

Migraine in cervical artery dissection and ischemic stroke patients

TM Metso, T Tatlisumak, S Debette, J Dallongeville, ST Engelter, PA Lyrer, V Thijs, A Bersano, S Abboud, D Leys, C Grond-Ginsbach, M Kloss, E Touze, A Pezzini, AJ Metso

NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012

Abstract

OBJECTIVE: Several small to medium-sized studies indicated a link between cervical artery dissection (CeAD) and migraine. Migrainous CeAD patients were suggested to have different clinical characteristics compared to nonmigraine CeAD patients. We tested these hypotheses in the large Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) population. METHODS: A total of 968 CeAD patients and 653 patients with an ischemic stroke of a cause other than CeAD (non-CeAD IS) were recruited. CeAD patients with stroke (CeAD(stroke), n = 635) were compared with non-CeAD IS patients regarding migraine, clinical characteristics, and outcome. CeAD patients with and without migraine were compared ..

View full abstract

Grants

Funding Acknowledgements

Dr. Metso has received research support from the Finnish Medical Foundation, Helsinki University Medical Foundation, Orion Farmos Research Foundation, Paivikki and Sakari Sohlberg's Foundation, Maire Taponen Foundation, the Lilly Foundation, Paavo Ilmari Ahvenainen Foundation, Aarne and Aili Turunen Foundation, Aarne Koskelo Foundation, Maud Kuistila Foundation, Emil Aaltonen Foundation, the Finnish Brain Foundation, and the Alfred Kordelin Foundation. Dr. Tatlisumak serves on scientific advisory boards for Boehringer Ingelheim and Mitsubishi Tanabe Pharma Corporation; has received funding for travel from Boehringer Ingelheim; serves/has served on the editorial board of Stroke, Current Vascular Pharmacology, The Open Pharmacology Journal, Clinics of Turkey, Clinics of Turkey/Neurology, The Open Cardiovascular Medicine Journal, Recent Patents on Biotechnology, Cerebrovascular Diseases, Recent Patents on CNS Drug Discovery, Experimental and Translational Stroke Medicine, Stroke Research and Treatment, BMC Journal of Experimental and Translational Stroke Medicine, and Frontiers in Stroke and was founding Editor-in-chief of Case Reports in Neurology; has filed patents re: Stanniocalcin proteins and nucleic acids and methods based thereon, New therapeutic uses (method to prevent brain edema and reperfusion injury) and Thrombolytic compositions (method to prevent postthrombolytic hemorrhage formation); serves as a consultant for Boehringer Ingelheim, PhotoThera, Mitsubishi Tanabe Pharma Corporation BrainsGate, Schering-Plough Corp., Lundbeck Inc., sanofi-aventis, Concentric Medical, Inc.; and has received research support from Boehringer Ingelheim, the Finnish Academy of Sciences, the European Union, Biocentrum Finland, Biocentrum Helsinki, Sigrid Juselius Foundation, Liv och Halsa, and Maire Taponen Foundation. Dr. Debette reports no disclosures. Dr. Dallongeville serves on scientific advisory boards for AstraZeneca, Danone, Merck Sharp & Dohme, and sanofi-aventis; has received funding for travel and speaker honoraria from AstraZeneca and Novartis; and receives research support from AstraZeneca, Pfizer Inc, sanofi-aventis, INSERM, ANR, and CPER. Dr. Engelter has received funding for travel from Boehringer Ingelheim and Shire plc; serves on the editorial board of Stroke; and receives research support from the Kathe-Zingg-Schwichtenberg-Fonds of the Swiss Academy of Medical Sciences, the Swiss Heart Foundation, and Swiss National Funds. Dr. Lyrer served on a scientific advisory board for Bayer Schering Pharma; serves as Co-Editor for Neurologie und Psychiatrie, and on the editorial board of Swiss Archives of Neurology and Psychiatry; and receives research support from the Swiss National Foundation and the Swiss Heart Foundation. Dr. Thijs, Dr. Bersano, and Dr. Abboud report no disclosures. Dr. Leys serves on a scientific advisory board for Bayer Schering Pharma; served as an Associate Editor of the Journal of Neurology, Neurosurgery and Psychiatry and serves as an editorial board member of Stroke and Cerebrovascular Diseases; serves as a consultant for Allergan, Inc.; and receives research support from PHRC. Dr. Grond-Ginsbach, Dr. Kloss, Dr. Touze, and Dr. Pezzini report no disclosures. Dr. Metso has received research support from the Finnish Medical Foundation and the Alfred Kordelin Foundation.